Zhang LF, Chen LX, Yang WJ, Hu B. Albumin-bilirubin score in non-malignant liver and other diseases. World J Gastroenterol 2024; 30(41): 4481-4483 [PMID: 39534421 DOI: 10.3748/wjg.v30.i41.4481]
Corresponding Author of This Article
Bing Hu, MD, Professor, Department of Gastroenterology and Hepatology, West China Hospital, Sichuan University, No. 37 Guoxue Alley, Chengdu 610041, Sichuan Province, China. hubing@wchscu.edu.cn
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Nov 7, 2024; 30(41): 4481-4483 Published online Nov 7, 2024. doi: 10.3748/wjg.v30.i41.4481
Albumin-bilirubin score in non-malignant liver and other diseases
Li-Fan Zhang, Liu-Xiang Chen, Wen-Juan Yang, Bing Hu
Li-Fan Zhang, Liu-Xiang Chen, Wen-Juan Yang, Bing Hu, Department of Gastroenterology and Hepatology, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China
Li-Fan Zhang, Liu-Xiang Chen, Wen-Juan Yang, Bing Hu, Digestive Endoscopy Medical Engineering Research Laboratory, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China
Author contributions: Zhang LF drafted the manuscript; Chen LX, Yang WJ, and Hu B revised the manuscript; All authors read and approved the final version of the manuscript to be published.
Supported bythe Natural Science Foundation of Sichuan Province, China, No. 2022NSFSC0819.
Conflict-of-interest statement: All authors declare no conflicts of interest in publishing the manuscript.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Bing Hu, MD, Professor, Department of Gastroenterology and Hepatology, West China Hospital, Sichuan University, No. 37 Guoxue Alley, Chengdu 610041, Sichuan Province, China. hubing@wchscu.edu.cn
Received: March 27, 2024 Revised: September 17, 2024 Accepted: September 29, 2024 Published online: November 7, 2024 Processing time: 209 Days and 13.2 Hours
Abstract
The albumin-bilirubin (ALBI) score is derived from albumin and bilirubin levels. Currently, the ALBI score is widely used in various clinical settings. A recent article in the World Journal of Gastroenterology summarized the application of the ALBI score in various non-malignant liver diseases. The ALBI score has a predictive power that is superior or non-inferior to established numerous measures. This may be related to its contiguity, sensitivity, and inclusion of albumin. While we recognize the good results of the ALBI score in a number of diseases, the ALBI score also has limitations. Variation studies for population characteristics and other factors should be performed to validate the performance of ALBI. Further modifications or optimization of ALBI scores should be taken into account.
Core Tip: A recent article in the World Journal of Gastroenterology reviewed the application of the albumin-bilirubin (ALBI) score in various liver diseases. The ALBI score shows predictive power comparable to established measures, possibly due to its continuity, sensitivity, and inclusion of albumin. However, despite promising results, the ALBI score has limitations. We believe population-specific validation studies and consideration of modifying factors are essential to ensure its accuracy and reliability in diverse patient populations.
